On January 12, Eli Lilly announced a five-year, up to $1 billion partnership with Nvidia to establish an AI-driven drug discovery lab in the San Francisco Bay area. The facility will combine Lilly’s extensive clinical success–failure datasets with Nvidia’s Vera Rubin AI processors, aiming to reduce early-stage development timelines that traditionally span over a decade and cost in excess of $1 billion per compound. This follows Lilly’s 2025 launch of what it termed the industry’s most powerful supercomputer and the 2024 rollout of TuneLab, its free AI platform for smaller biotechs, underscoring a multi-pronged approach to leverage machine learning for higher success rates and shorter cycle times.

Lilly’s tirzepatide franchise, marketed as Zepbound for obesity and Mounjaro for diabetes, delivered blockbuster performance in Q3, driving quarterly revenue to $17.6 billion, a 54% year-over-year increase. Earnings per share soared 480% to $6.21, propelled by the peptide’s status as the world’s top-selling medicine in that period. Management forecasts that tirzepatide will remain a primary growth engine through 2030, with additional upside from the impending launch of oral orforglipron and advanced pipeline candidates such as retatrutide, which continue to post superior Phase II trial outcomes in metabolic indications.

Investor sentiment was tested when reports indicated the FDA has postponed its ruling on Lilly’s oral obesity pill, orforglipron, pushing the decision timeline into April. While the delay allows Novo Nordisk extended market exclusivity runway for its competing oral therapy, analysts view the setback as a tactical repricing event rather than a fundamental change to Lilly’s long-term obesity franchise prospects. The postponement underscores regulatory risk in drug approval but also reinforces the value of Lilly’s diversified metabolic portfolio and robust cash generation to sustain R&D and shareholder returns.

Beyond the metabolic franchise, Lilly has broadened its pipeline with recent approvals in dermatology (Ebglyss), oncology (Jaypirca) and neurology (Kisunla), and continues advancing candidates across immunology, rare diseases and pain management. The company’s commitment to shareholder returns is evident in a 103.5% increase in its dividend over the past five years, funded by strong free cash flow generation. With an 83% gross margin and nearly $1 trillion in market capitalization, Lilly’s balance sheet provides flexibility for further bolt-on acquisitions and sustained dividend growth, underpinning its investment appeal despite current valuation multiples.